ProCE Banner Activity

CME

TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option

Video

In this webcast, learn the latest clinical evidence for incorporating TROP-2–targeted antibody–drug conjugates into the care of patients with advanced NSCLC.

European Learners: 1.00 EBAC® CE Credit

Physicians: Maximum of 1.25 AMA PRA Category 1 Credits

Released: April 10, 2024

Expiration: April 09, 2025

Share

Faculty

Luis Paz-Ares

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

David Planchard

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Paris-Saclay University
International Center for Thoracic Cancers
Villejuif, France

Helena Yu

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from Gilead Sciences, Inc.

Gilead Sciences, Inc.

Target Audience

This program is intended for oncologists, researchers, and other healthcare professionals caring for patients with non-small-cell lung cancer.

Program Learning Goal

The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Non-Small Cell Lung Cancer (NSCLC).

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Describe the biological rationale for targeting TROP-2 and features that differentiate the ADCs targeting TROP-2

  • Select patients with NSCLC for treatment with TROP-2–targeting ADCs that aligns with the eligibility criteria of the major studies and is personalized for optimal outcome

  • Develop monitoring (including early identification), management (including prophylaxis), and supportive care plans to limit treatment-related adverse events associated with TROP-2–directed ADCs

  • Evaluate the rationale for combination strategies with TROP-2–targeting ADCs and the clinical trials of TROP-2–targeting combinations in various NSCLC disease settings

  • Offer participation in clinical trials of investigational TROP-2–targeting ADCs as part of therapeutic strategies for eligible patients with NSCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

In compliance with EBAC guidelines, all speakers/chairpersons participating in this programme have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CE activities.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Luis Paz-Ares, MD, PhD

Chair of the Medical Oncology Department
Hospital Universitario 12 de Octubre
Associate Professor
Universidad Complutense de Madrid
Head of the Lung Cancer Unit
CNIO (Spanish National Cancer Research Center)
Madrid, Spain

Luis Paz-Ares, MD, PhD: consultant/advisor/speaker: AbbVie, Amgen, AstraZeneca, Bayer, BeiGene, Bristol Myers Squibb, Gilead, Lilly, Merck-Serono, MSD, Novartis, Pfizer, PharmaMar, Roche, Sanofi; grant/contract: AstraZeneca, Bristol Myers Squibb, MSD, Pfizer, PharmaMar; honoraria/speakers bureau: AstraZeneca, Janssen, Merck, Mirati, Sanofi.

David Planchard, MD, PhD

Head of Thoracic Cancer Group
Department of Medical Oncology
Gustave Roussy
Paris-Saclay University
International Center for Thoracic Cancers
Villejuif, France

David Planchard, MD, PhD: consultant/advisor/speaker: AbbVie, AstraZeneca, ArriVent, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Daiichi Sankyo, Janssen, Lilly, Merck, Mirati, Novartis, Pfizer, Pierre-Fabre, Roche, Seagen, Takeda.

Helena Yu, MD

Associate Professor
Research Director
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Helena Yu, MD: consultant/advisor/speaker: Amgen, AstraZeneca, Black Diamond, Blueprint Medicine, Daiichi Sankyo, Janssen.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.25 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from April 10, 2024, through April 09, 2025:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

EBAC® Accreditation 

This program is accredited by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC) for 1.0 external CE credit. Each participant should claim only those hours of credit that have actually been spent in the educational activity.